Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression.

by Livia Raso-Barnett, Balazs Banky, Tamas Barbai, Peter Becsagh, Jozsef Timar, Erzsebet Raso
Published 2013-01-01

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

by Andrea Uhlyarik, Violetta Piurko, Zsuzsanna Papai, Erzsebet Raso, Erika Lahm, Edina Kiss, Marta Sikter, Jozsef Vachaja, Istvan Kenessey, Jozsef Timar
Published 2020-03-01

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, mult...

by Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yilmaz Turay, Ahmet Demirkazik, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó, Gyula Ostoros
Published 2018-05-01

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

by Áron Kristof Ghimessy, Áron Gellert, Erzsebet Schlegl, Balazs Hegedus, Erzsebet Raso, Tamas Barbai, Jozsef Timar, Gyula Ostoros, Zsolt Megyesfalvi, Balazs Gieszer, Judit Moldvay, Ferenc Renyi-Vamos, Zoltan Lohinai, Mir Alireza Hoda, Thomas Klikovits, Walter Klepetko, Viktoria Laszlo, Balazs Dome
Published 2019-10-01